The Middle East and Africa (MEA) biologics and biosimilars market is poised for substantial growth, with an expected valuation of US$ 512.6 million in 2023. The market is projected to expand at a compound annual growth rate (CAGR) of 5.5%, reaching approximately US$ 875.6 million by 2033. According to a recent study by Future Market …